SCHEMBL6286437

SCHEMBL6286437

Cn1nc(C(=O)NCc2ccc(Cl)cc2)c(=O)c2cc(I)cnc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 2/20 0.47
GALR3 O60755 1/20 0.47
NR2F2 P24468 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
NR3C1 P04150 3/20 0.45
ALDH1A1 P00352 1/20 0.45
POLB P06746 1/20 0.45
PKM P14618 1/20 0.45
MAPT P10636 2/20 0.44
THRB P10828 1/20 0.43
CNR1 P21554 3/20 0.43
GAA P10253 1/20 0.43
ABCB1 P08183 3/20 0.43
CNR2 P34972 2/20 0.43
HPGD P15428 2/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6289009 0.84 SMN1; SMN2 (0.44) SMN1; SMN2LMNAGALR3NR2F2RAB9A
SCHEMBL6287239 0.83 SMN1; SMN2 (0.46) SMN1; SMN2LMNAGALR3NR2F2RAB9A
SCHEMBL6695126 0.83 KMT2A (0.48) SMN1; SMN2LMNAGALR3NR2F2RAB9A
SCHEMBL6283724 0.81 RXFP1 (0.43) SMN1; SMN2LMNAGALR3NR2F2RAB9A
SCHEMBL6288581 0.80 KCNH2 (0.53) SMN1; SMN2KMT2AALDH1A1ABCB1
SCHEMBL6284984 0.79 KMT2A (0.48) SMN1; SMN2LMNARAB9AKMT2AALDH1A1
SCHEMBL6695762 0.75 SMN1; SMN2 (0.52) SMN1; SMN2LMNAGALR3NR2F2RAB9A
SCHEMBL6287194 0.75 PTGER4 (0.43) SMN1; SMN2LMNAGALR3NR2F2RAB9A
SCHEMBL6284890 0.74 SMN1; SMN2 (0.47) SMN1; SMN2LMNAGALR3NR2F2RAB9A
SCHEMBL6713689 0.74 GAA (0.46) LMNAKMT2AALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6903097-B2 Heterocycle carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY (US) 2005-06-07 US disclosed
US-20040142928-A1 Heterocycle carboxamides as antiviral agents BUNDY GORDON L (US) 2004-07-22 US disclosed
US-20030207880-A1 Heterocycle carboxamides as antiviral agents BUNDY GORDON L (US) 2003-11-06 US disclosed
US-6559145-B2 Herpes virus PHARMACIA & UPJOHN COMPANY 2003-05-06 US disclosed
EP-1301493-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-04-16 EP disclosed
US-20020025960-A1 Heterocycle carboxamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2002-02-28 US disclosed
WO-2002004444-A2 HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142928-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 SMN1; SMN2 4321/4885LMNA 4330/4885GALR3 3507/4885
US-20020025960-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 SMN1; SMN2 4321/4885LMNA 4330/4885GALR3 3507/4885
US-20030207880-A1 Heterocycle carboxamides as antiviral agents ZC3HAV1, ZC3HAV1L, HDAC1 SMN1; SMN2 4321/4885LMNA 4330/4885GALR3 3507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.